Zydus Lifesciences shares came under selling pressure on June 3 after the company informed exchanges that it had received a warning letter from the USFDA relating to its manufacturing facility in Baddi, Himachal Pradesh. The development led to concerns among investors regarding the facility's regulatory compliance status and future approvals.

The stock fell as much as 2.64% during intraday trading before recovering part of the losses. At around 11:30 am IST, the stock was trading at ₹1,067.30 on the NSE, down about 1% from the previous close.

In its regulatory filing, Zydus clarified that it does not anticipate any impact on ongoing operations, product supplies, or overall business performance due to the warning letter. The company indicated that it is engaging with the USFDA and will undertake the necessary corrective actions to address the regulator's observations.

The Baddi facility has been under regulatory scrutiny in the past. In August 2025, a USFDA inspection at the plant concluded with four observations, with the company noting that none were related to data integrity issues. The facility subsequently received an Establishment Inspection Report (EIR), indicating closure of that inspection cycle.

Warning letters are issued by the USFDA when the regulator identifies significant deviations from current Good Manufacturing Practices (cGMP) or other regulatory requirements. While such letters do not necessarily halt production or exports, companies are required to implement corrective and preventive actions and provide satisfactory responses to the regulator.

The latest development adds to the heightened focus on regulatory compliance across Indian pharmaceutical manufacturers serving the US market, where FDA inspections remain a critical factor influencing approvals, product launches, and investor sentiment.